TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05351502
Drug: Nitric Oxide selected dose
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratumoral injection of selected does on gNO
Study: NCT03617445
Drug: FMT oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules, single dose of 5 capsules
Study: NCT06445881
Drug: Modified Si Jun Zi Tang
Normalized name: Calagel Reformulated Jun 2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
Study: NCT06528665
Drug: ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned.
Study: NCT05485584
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT05974501
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
Study: NCT05974501
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg administered via IV once postoperatively within 24 hours for pain and swelling
Study: NCT05040568
Drug: Expanded CB-NK cells
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05040568
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05304377
Drug: ELVN-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once or twice daily
Study: NCT06205602
Drug: 3BNC117-LS
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg to be administered via IV at Step 1 (Day 1)
Study: NCT06205602
Drug: Placebo for 3BNC117-LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
Study: NCT06205602
Drug: Placebo for 10-1074-LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
Study: NCT06449781
Drug: Lutetium (177Lu) vipivotide tetraxetan
Normalized name: lutetium (177Lu) vipivotide tetraxetan
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
Study: NCT05368974
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral exposure during documented pregnancy
Study: NCT05618587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive pill
Study: NCT05256654
Drug: LY3561774
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05256654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05353179
Drug: NUCALA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUCALA® is a humanized monoclonal antibody of IgG1 injection
Study: NCT06097169
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Study: NCT06285214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Study: NCT04974151
Drug: Amlodipine besylate And Folic Acid
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
Study: NCT05000281
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg Ibuprofen 3 times a day for up to six weeks.
Study: NCT04974151
Drug: Amlodipine folic acid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
Study: NCT06390319
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT06390319
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO.
Study: NCT06390319
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, PO or intramuscular (IM).
Study: NCT06452277
Drug: BAY2927088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral
Study: NCT05935098
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Study: NCT05417282
Drug: MW151
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
Study: NCT01582022
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: local application for 5 minutes
Study: NCT05072704
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
Study: NCT05742399
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional gel having the same color, form and packaging
Study: NCT06146101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel capsule
Study: NCT06146101
Drug: IHL-42X (Optimal Dose)
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Softgel capsule
Study: NCT05618119
Drug: [18F]MC225
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]MC225 PET scan
Study: NCT04639050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
Study: NCT06527235
Drug: ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall
Approvals — FDA: no, EMA: no, PMDA: no
Description: The perimeniscal injections will be guided by ultrasound with an 18 MHz linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of isotonic saline injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
Study: NCT06308367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05772104
Drug: Shugan Jieyu Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 4 Capsules, BID
Study: NCT05772104
Drug: Shugan Jieyu Capsules Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID
Study: NCT05949281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once-daily
Study: NCT05271630
Drug: Immunomodulatory Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
Study: NCT05271630
Drug: Proteasome Inhibitor
Normalized name: Proteasome inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
Study: NCT06239116
Drug: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
Study: NCT06239116
Drug: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
Study: NCT06239116
Drug: Part C: RM-718
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of RM-718 (specific to Part C dose cohorts)
Study: NCT04810819
Drug: Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
Study: NCT04810819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00965315
Drug: Rosuvastatin,SFC fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Rosuvastatin 10 mg once daily~2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg
Study: NCT05679765
Drug: Greater Occipital Nerve Block with 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided Greater occipital nerve block on the side of headache
Study: NCT05487404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 oral doses of placebo
Study: NCT04685616
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT06297590
Drug: LY3954068
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IT
Study: NCT06297590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IT
Study: NCT06509139
Drug: Tetracycline Pill
Normalized name: tetracycline Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Study: NCT05848258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05005793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at 0.5 mEq/kg-lean body weight/day
Study: NCT05514483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
Study: NCT06450262
Drug: Synjardy® 12.5mg/1000mg film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
Study: NCT06225570
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm aims to serve as the comparison group. Tetracycline antibiotics are the current standard of care for the treatment of moderate acne.
Study: NCT05559359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given SC
Study: NCT05559359
Drug: Topical Corticosteroid (TCS)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCS administered
Study: NCT06657768
Drug: LY4006895
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06657768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06220669
Drug: LY3541860
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06220669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06679959
Drug: ASC30
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection, for subcutaneous use
Study: NCT04535609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT05943535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered QID
Study: NCT06097364
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion
Study: NCT06097364
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT05679908
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will spray placebo nasal spray once into each nostril.
Study: NCT05816252
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) infusion (Q2W or Q3W)
Study: NCT05592275
Drug: LY3540378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05592275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06379971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
Study: NCT06379971
Drug: Choline
Normalized name: Choline
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
Study: NCT05713877
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
Study: NCT05912244
Drug: IO102/IO103
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
Study: NCT04803539
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
Study: NCT04803539
Drug: capecitabine + camrelizumab + apatinib
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
Study: NCT05713877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
Study: NCT06205719
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ug/kg Remifentanil
Study: NCT05156320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered every 4 weeks by intravenous (IV) infusion.
Study: NCT06081283
Drug: Phosphenytoin
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pediatric population Loading dose 20 mg PE/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day. Max dose 300mg PE/day. Adult population Loading dose 20 mg/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day.
Study: NCT06126081
Drug: GDMT
Normalized name: Guideline-Directed Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
Study: NCT06378580
Drug: AG/FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity.
Study: NCT05005819
Drug: [18F] APN-1607
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo PET imaging using \[18F\]APN-1607.
Study: NCT06541704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT05114096
Drug: Celestone + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo.
Study: NCT05114096
Drug: Celestone + Celestone
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone.
Study: NCT05877573
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200mg/m2 d1-14 q3w
Study: NCT06390241
Drug: Avidin-biotin-Dota-90Y
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
Study: NCT06522997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching with BAY3283142
Study: NCT06297616
Drug: LY3841136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06297616
Drug: LY3841136-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05731427
Drug: Macrolides
Normalized name: Macrolides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before or after 6 months of treatment with macrolides for patients with bronchiectasis
Study: NCT04609761
Drug: Privigen Injectable Product (Intravenous Immunoglobulin)
Normalized name: Privigen Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
Study: NCT05635708
Drug: LBL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT06731413
Drug: Reduced Dose of Chemotherapy and Immunotherapy
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
Study: NCT06088875
Drug: Nebulization
Normalized name: AMPUL FOR NEBULIZATION (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
Study: NCT06088875
Drug: Spray-as-you-go
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
Study: NCT04619927
Drug: Poor metabolisers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
Study: NCT04619927
Drug: Intermediate metabolisers
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75mg twice daily
Study: NCT06232252
Drug: Placebo matching BI 765423
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 765423
Study: NCT04442412
Drug: RCHOP o R-miniCHOP at standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses
Study: NCT04901676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06159062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo do not consist any active ingredients.
Study: NCT06483659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Saline
Study: NCT05106517
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Iv zoledronic acid and placebo /6 months subcutaneously
Study: NCT06400303
Drug: Standard lymphodepletion regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lymphodepletion regimen